Merck ($MRK) and Pfizer ($PFE) announced that they have a collaboration agreement in place with Dako, a Agilent Technologies (A) company for the development of a potential companion diagnostic test used to assess programmed death-ligand 1 protein expression levels in tumor tissues and its microenvironment.
(0)
(0)